Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label induction and maintenance study of oral tofacitinib in pediatric ulcerative colitis
jRCT2071210075Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2021
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of tofacitinib in autoimmune colitis, sponsored by Pfizer. Primary endpoint: Remission by central read Mayo score at maintenance Week 44. Started Aug 2021; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071210075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210075.